CAMAGÜEY.- At the María Curie provincial cancer hospital, national clinical trials with therapeutic vaccines are being carried out, linked to the Molecular Immunology (CIM) and Genetic Engineering and Biotechnology (CIGB) centers.
The MSc. Lourdes C. de Quesada Camacho and Coordinator of Clinical Trials at that institution, announced that with the CIM they execute those related to patients with non-small cell lung cancer (NSCLC) in advanced stages, in which the growth factor is determined epidermal (EGF) and depending on the resulting figures, an immunotherapy treatment already registered with CIMAvax-EGF is applied, according to the criteria of their attending physician.
At this time, added the also specialist in Clinical Biochemistry, a multicenter study is being organized, after the approvals for its execution, for patients with titles below those conceived, approved by their attending physician and who have responded to oncological therapy or with stable disease, with VAXIRA or NIMOTUZUMAB.
To treat lung tumors in advanced stages with diagnosis of small cells, there is a clinical trial: Active immunotherapy with the vaccine preparation NGcGM3 / VSSP, phase I / II, stages in which the attending physician evaluates whether the patient is tributary to the immunotherapy under study.
On the other hand, patients with asymptomatic or mildly symptomatic metastatic prostate cancer, without other lines of treatment, who do not use pain relief medications such as tramadol or morphine, and with the prior evaluation of their attending physician, another clinical trial with the therapeutic vaccine CIMAvax-EGF®.
With the Center for Genetic Engineering and Biotechnology, the hospital institution cares for people with study III and IV renal cell carcinoma, as always evaluated by their attending physician and who meet the established criteria, and those who qualify receive the HeberFERON or Heberon alpha, randomly.
In all the cases mentioned under informed consent.
Lourdes C. de Quesada assured that “María Curie” continues to treat those patients with other locations, whose quality of life and survival allow them to continue with the immunotherapies of both promoter centers, despite the limitations imposed by the blockade of the United States to Cuba, and those added by the appearance of SARS-CoV-2 that causes COVID-19, a pandemic for just over a year.
Translated by Linet Acuña Quilez